ProBioGen and Boehringer Ingelheim enter into Strategic Production Alliance
Berlin, Germany, 29 April 2008
ProBioGen AG, a leading biotechnology company in mammalian and non-mammalian cell engineering and production, today announced a strategic production agreement with Boehringer Ingelheim. Under the agreement, ProBioGen will integrate some of Boehringer Ingelheim's technologies to accommodate a seamless process and technology transfer from pilot and medium-scale to commercial-scale production capacities. ProBioGen's clients will thereby gain access to Boehringer Ingelheim's manufacturing technology platform and large-scale commercial production. In addition, Boehringer Ingelheim's clients and partners will benefit from ProBioGen's expertise in process development and manufacturing.
"ProBioGen´s strategic production alliance with Boehringer Ingelheim is an important milestone in our commercial strategy," said Michael Schlenk, Chief Executive Officer of ProBioGen. "For one, our clients will gain access to one of the leading commercial-scale production platforms, but we will also be able to expand our client base and have started to build additional production capabilities to meet increased client demand."
"ProBioGen’s complementing services in process development and clinical material supply represent an excellent gain for Boehringer Ingelheims woldwide strategic manufacturing network. The provision of compatible process formats and close interaction with Boehringer Ingelheim integrates state of the art and time to clinic development at ProBioGen with seamless technology transfer to Boehringer Ingelheim’s commercial manufacturing", commented Prof. Dr. Dr. h. c. Rolf G. Werner, Corporate Senior Vice President of the Corporate Division Biopharmaceuticals, Boehringer Ingelheim GmbH.